Naturewise Biotech and Medicals Corporation

Gnt Biotech & Medicals Corporation

Li-Ling Chi

Chia-Nan Chen

Wei-Jan Huang

Chung-Yang Huang

Chia-Wei Lin

Yu-Chen Huang

Wei-Jung Chen

Ai-Ling Chen

Chi-Yun Lee

Jing-Shi Huang

Ye-Su Chao

Yi-Hong Wu

Meng-Ju Tsai

Ying-Chen Yang

Ching-Yi Lin

Chih-Hsiang Huang

Yu-Jung Liao

Wan-Yi Hsu

Chiou-Ping You

Huan-Yu Lin

Ching-yi Lin

Chen Al-Ling

The invention provides a pH-sensitive linker that can simultaneously bind metallic nanoparticles and one or more agents with various molecular size. The linker of the invention can deliver the agents into cells involved in disease processes or close to cells so that the agents can selectively target and effect on the cells. The target delivery provided by the linker of the invention can be used for example for disease sensing, imaging, drug delivery, and therapy.

PH-sensitive linkers for delivering a therapeutic agent

The invention relates to a method of using metal nanoparticle or metallic particle to promote neurite outgrowth and treat and/or prevent neurological disorders. Particularly, the method of the invention uses gold nanoparticles or gold particles to promote neurite outgrowth and treat and/or prevent neurological disorders.

Use of nano metal in promoting neurite outgrowth and treatment and/or prevention of neurological disorders

The present invention is directed to a novel use of prenylflavanone compounds for control of blood glucose and treatment or prevention of diabetes.

Prenylflavanone compounds for modulating diabetes

The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly produced thereform. Also provided is a method of promoting the growth of the larva of a queen bee comprising feeding the larva of the queen bee a royal jelly of the invention. Further provided is a method of producing bee larva, pupa and queen bees with sizes larger than normal.

Use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly

The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-cancer, anti-diabetic, and anti-neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Spinocerebellar Ataxias (SCA), and human spinal muscular atrophy (SMA).

Cinnamic compounds and derivatives therefrom for the inhibition of histone deacetylase

The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-neurodegenerative diseases and human spinal muscular atrophy (SMA).

Compounds for the inhibition of histone deacetylase

Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase

Growing community of inventors

Taipei, Taiwan

Li-Ling Chi